Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (25): 2697–2708.

https://doi.org/10.1182/blood.2022016624

Published: 2022

Includes: Supplemental data

Journal Articles

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Zhen Han, Xiwei Wu, Yate-Ching Yuan, Hanjun Qin, Chingyu Su, Jasmine Zain, Oleg E Akilov, Steve T Rosen, Mingye Feng, Christiane Querfeld

Blood (2022) 140 (Supplement 1): 6376–6377.

https://doi.org/10.1182/blood-2022-167670

Published: 2022

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 9387–9389.

https://doi.org/10.1182/blood-2022-169432

Published: 2022

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Ann S. LaCasce, David C. Fisher, Alex F. Herrera, Caron A. Jacobson, Austin I. Kim, Reid W Merryman, Oreofe O. Odejide, Samuel Ng, Yago Nieto, Craig S. Sauter, Gunjan L. Shah, Jasmine Zain, Philippe Armand, Eric D Jacobsen

Blood (2022) 140 (Supplement 1): 1185–1187.

https://doi.org/10.1182/blood-2022-164839

Published: 2022

Journal Articles

The Impact of Chemotherapy on Phenotype and Function of Non-Malignant T-Cells in Patients with T-Cell Lymphoma

Meryl Colton, Kimberly Jordan, Eduardo Davila, Xander Bradeen, Jasmine Zain, Pierluigi Porcu, Bradley M. Haverkos

Blood (2022) 140 (Supplement 1): 11938–11940.

https://doi.org/10.1182/blood-2022-169691

Published: 2022

Journal Articles

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Bradley M. Haverkos, Jasmine Zain, Manali K. Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 2308–2309.

https://doi.org/10.1182/blood-2022-168979

Published: 2022

Journal Articles

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (19): 2024–2036.

https://doi.org/10.1182/blood.2022016747

Published: 2022

Includes: Supplemental data

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Jonathan E Brammer, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Eric D Jacobsen, Giuseppe Gritti, Debra Litwak, David Cohan, Danica J Katz, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2021-148939

Published: 2021

Journal Articles

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

Brad Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 2444.

https://doi.org/10.1182/blood-2021-152617

Published: 2021

Journal Articles

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani

Blood (2021) 138 (Supplement 1): 2489.

https://doi.org/10.1182/blood-2021-153591

Published: 2021

Journal Articles

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Farah R Abdulla, Weiwei Zhang, Xiwei Wu, Kord Honda, Hanjun Qin, Hyejin Cho, Christiane Querfeld, Jasmine Zain, Steven T. Rosen, Wing C. Chan, Vishwas Parekh, Joo Y. Song

Blood (2021) 138 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2021-152051

Published: 2021

Journal Articles

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana A. Feldman, Jonathan E Brammer, Lu Chen, Leslie L. Popplewell, Lihua E Budde, Matthew Mei, Lori A. Leslie, Ranjit Nair, Chitra Hosing, Lacolle Peters, Stephen J Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 133.

https://doi.org/10.1182/blood-2021-151105

Published: 2021

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MDPhD, Ni-Chun Tsai, MS, Joycelynne Palmer, PhD, Xochiquetzal U. Martinez, MD, Farah Abdulla, MD, Xiwei Wu, PhD, Steven T. Rosen, MD, Jasmine Zain, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-143354

Published: 2020

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, PhD, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, MS, David Yamauchi, MD, Erasmus Kofi Poku, PharmD, Van Eric Biglang-awa, PharmD, John E. Shively, PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141114

Published: 2020

Journal Articles

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Christiane Querfeld, MDPhD, Basem M. William, MDMRCP, Lubomir Sokol, MD PhD, Oleg Akilov, MD, Brian Poligone, MD PhD, Jasmine Zain, MD, Yutaka Tagaya, MD PhD, Nazli Azimi, PhD PharmD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143135

Published: 2020

NARROW

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

The Impact of Chemotherapy on Phenotype and Function of Non-Malignant T-Cells in Patients with T-Cell Lymphoma

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only